Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Shinji Ishikawa, Hiroshi Sawayama, Akinobu Matsuo, Ryojin Uchino, Shinobu Honda, Masahiko Hirota, Hideo Baba
Background: Stage III colorectal cancer is an indication for adjuvant chemotherapy; however, there is no definite view on the selection of regimen. If the recurrence can be predicted, it can serve as the indicator of regimen selection. The present study aimed to predict the recurrence of stage III colorectal cancer by constructing a simple scoring system. Methods: The information of stage III cases that underwent curative surgery was obtained from two facilities and analyzed...
January 4, 2019: Japanese Journal of Clinical Oncology
Fuyuhiko Motoi, Tomoo Kosuge, Hideki Ueno, Hiroki Yamaue, Sohei Satoi, Masayuki Sho, Goro Honda, Ippei Matsumoto, Keita Wada, Junji Furuse, Yutaka Matsuyama, Michiaki Unno
A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled after the diagnosis of resectable or borderline resectable by portal vein involvement pancreatic cancer with histological confirmation. They were randomly assigned to either neoadjuvant chemotherapy or upfront surgery. Adjuvant chemotherapy using S-1 was administered for 6 months to patients with curative resection who fully recovered within 10 weeks after surgery in both arms...
January 4, 2019: Japanese Journal of Clinical Oncology
Takashi Mima, Makoto Ohori, Yosuke Hirasawa, Ryuji Mikami, Ayako Arai, Takeshi Hashimoto, Naoya Satake, Tatsuo Gondo, Yoshihiro Nakagami, Kazunori Namiki, Koichi Tokuuye, Yoshio Ohno
Objectives: The aim of this study was to identify risk factors to predict a biochemical recurrence (BCR) in patients treated with salvage radiation therapy (SRT) after radical prostatectomy (RP). Methods: We retrospectively reviewed 122 Japanese patients who received SRT for BCR after RP. Using uni- and multivariate Cox proportional hazard models, we identified the predictive factors of BCR after SRT. Results: With a median follow-up of 61...
January 4, 2019: Japanese Journal of Clinical Oncology
Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue
According to fluorescent in situ hybridization, t(11;14) is the most common cytogenetic abnormality in amyloid light-chain (AL) amyloidosis, but its prevalence in patients with AL amyloidosis and concurrent multiple myeloma (MM) remains unknown. We aimed to examine the prevalence of t(11;14) and the differences in clinical characteristics of patients with t(11;14) who had AL amyloidosis with or without concurrent MM. We retrospectively analyzed 40 patients with AL amyloidosis between January 2008 and January 2018 at our institution...
January 4, 2019: Japanese Journal of Clinical Oncology
Dai Shida, Yukihide Kanemitsu, Tetsuya Hamaguchi, Yasuhiro Shimada
Background: The eighth edition of the tumor-node-metastasis classification of malignant tumors updates cancer staging according to the evidence accumulated in the last 8 years since the release of the tumor-node-metastasis seventh edition. This review focuses on the new staging system. Methods: The eight edition was compared with the seventh edition as well as the Japanese Classification of Colorcetal, Appendiceal, and Anal carcinoma ninth edition. Results: Of colon and rectum, the tumor-node-metastasis eighth edition expands the M category...
January 4, 2019: Japanese Journal of Clinical Oncology
Hideaki Kitahara, Yoshitaka Honma, Makoto Ueno, Yukihide Kanemitsu, Shinichi Ohkawa, Junki Mizusawa, Junji Furuse, Yasuhiro Shimada
A randomized phase III trial was initiated in May 2017 to confirm the superiority of post-operative therapy with capecitabine and oxaliplatin over observation in terms of relapse-free survival in patients with curatively resected small bowel adenocarcinoma. Total 150 patients will be enrolled from 20 Japanese institutions over a period of 6.5 years. Relapse-free survival is the primary endpoint, while the secondary endpoints are overall survival, disease-free survival as defined by the Japan Clinical Oncology Group (JCOG), disease-free survival as defined by the International Rare Cancer Initiative (IRCI), and adverse events...
December 24, 2018: Japanese Journal of Clinical Oncology
Kota Katanoda, Eiko Saito
No abstract text is available yet for this article.
December 21, 2018: Japanese Journal of Clinical Oncology
Akihiko Osaki, Kenichi Inoue, Hiroshi Sakai, Kazuhiko Yamada, Koichi Minato, Fumiyoshi Ohyanagi, Yutaka Tokuda, Norihiko Ikeda, Hiroshi Kagamu, Kaoru Kubota, Tomohide Tamura, Toshiaki Saeki
Objective: Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dose-response of oral netupitant in Japanese patients receiving highly emetogenic chemotherapy. Methods: Chemotherapy-naïve patients were randomized (1:1:1) to a single oral netupitant 30-, 100- or 300-mg dose before chemotherapy initiation...
December 20, 2018: Japanese Journal of Clinical Oncology
Kei Ito, Takuya Shimizuguchi, Katsuyuki Karasawa
Objective: While external beam radiotherapy boost has been one of the standard management options for locally advanced cervical cancer that is not treatable with intracavitary brachytherapy, its efficacy remains unclear. We assessed clinical outcomes in Japanese patients with cervical cancer who underwent external beam radiotherapy alone and identified related prognostic factors. Methods: Patients treated with definitive external beam radiotherapy for cervical cancer unsuitable for intracavitary brachytherapy, including whole pelvic irradiation and external beam radiotherapy boost, were retrospectively examined...
December 20, 2018: Japanese Journal of Clinical Oncology
Takeshi Nawa, Keisuke Fukui, Tomio Nakayama, Motoyasu Sagawa, Tohru Nakagawa, Hideo Ichimura, Tetsuya Mizoue
Objectives: To evaluate the effectiveness of lung cancer screening using low-dose computed tomography for the general population, we conducted a retrospective cohort study of screening for participants among Hitachi residents. Materials and Methods: Citizens aged 50-74 who underwent low-dose computed tomography screening at least once during 1998-2006 were defined as the computed tomography group, and those who underwent X-ray screening at least once during the same period, but did not receive low-dose computed tomography screening throughout the follow-up period, were defined as the XP group...
December 12, 2018: Japanese Journal of Clinical Oncology
Norikatsu Miyoshi, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori
The classical cancer therapies, including chemotherapy and radiation therapy, can initially show good results and tumor shrinkage; however, for most cancer patients disease recurrence is a common event. This tumor regrowth following therapy is now thought to depend on a small population of cancer stem cells (CSCs), which, similar to other stem cells, have the capacity for self-renewal and multipotent differentiation. Cancer stem cells have been identified based on cell surface protein expression in many tumor types, and for all diseases studied, this specific cell population is required for serial transplantation in animal models...
December 12, 2018: Japanese Journal of Clinical Oncology
Shingo Kato, Takuo Hayashi, Yoshiyuki Suehara, Haruka Hamanoue, Shoji Yamanaka, Yasushi Ichikawa, Takuma Higurashi, Kenichi Ohashi, Shigeo Yamaguchi, Yumi Nozaki, Yasuhisa Terao, Tsuyoshi Saito
Background: Application of next-generation DNA sequencing (NGS) has recently become increasingly common in the field of clinical oncology in several countries around the world. In Japan also, a system for applying NGS to routine clinical practice is gradually being established. During this process, we introduced in Japan the tumor-profiling MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) assay. Methods: We present here our initial experience with the use of MSK-IMPACT in 68 patients selected from two institutions in Japan between June 2016 and October 2017...
December 12, 2018: Japanese Journal of Clinical Oncology
Masataka Sawaki, Tadahiko Shien, Hiroji Iwata
The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging...
December 12, 2018: Japanese Journal of Clinical Oncology
Soo Jin Park, Jihyang Kim, Sung Nyun Kim, Eun Ji Lee, Soohyun Oh, Aeran Seol, Nara Lee, Suk Joon Chang, Hee Seung Kim
Background: We investigated the practice patterns of surgery for advanced ovarian cancer (AOC) through relevant international surveys. Methods: After searching for 878 studies on surgery for AOC till 2017, we extracted 18 questions with similar query and answer formats from eight studies. Among them, 5 and 13 were classified as comprehensive and procedure information. Results: In comprehensive information, there was a higher preference for optimal cytoreduction defined as no visible tumor (44%) compared with residual tumors <1 cm (38%) or <2 cm (2%) and omental disease involving the spleen or pancreas was more important as an intraoperative finding precluding optimal cytoreduction (35%) since 2010...
December 6, 2018: Japanese Journal of Clinical Oncology
Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Terufumi Kato, Shunichi Sugawara, Suresh S Ramalingam, Hirohiko Uchida, Rachel Hodge, Sarah L Vowler, Andrew Walding, Kazuhiko Nakagawa
Background: The FLAURA study was a multicenter, double-blind, Phase 3 study in which patients with previously untreated epidermal growth factor receptor mutation-positive advanced non-small-cell lung carcinoma were randomized 1:1 to oral osimertinib 80 mg once daily or standard-of-care (gefitinib 250 mg or erlotinib 150 mg, once daily) to compare safety and efficacy. In the overall FLAURA study, significantly better progression-free survival was shown with osimertinib versus standard-of-care...
December 1, 2018: Japanese Journal of Clinical Oncology
Takeru Kashiwada, Yoshinobu Saito, Yasuhiro Terasaki, Kakeru Hisakane, Susumu Takeuchi, Teppei Sugano, Akihiko Miyanaga, Rintaro Noro, Yuji Minegishi, Masahiro Seike, Kaoru Kubota, Akihiko Gemma
Background: Nanoparticle albumin-bound paclitaxel is indicated for the treatment of patients with lung cancer. It can induce interstitial lung disease, but the incidence of nanoparticle albumin-bound paclitaxel-associated interstitial lung disease in clinical practice has not been determined. We investigated the incidence of interstitial lung disease in patients with lung cancer who had received nanoparticle albumin-bound paclitaxel therapy at our institution. Methods: We reviewed clinical data for patients with advanced lung cancer who received nanoparticle albumin-bound paclitaxel with or without carboplatin or bevacizumab therapy at the Nippon Medical School Main Hospital between April 2013 and September 2017...
December 1, 2018: Japanese Journal of Clinical Oncology
Hiroyuki Arai, Yu Sunakawa, Takako Eguchi Nakajima
In the multimodality treatment strategy for gastric cancer, chemotherapy has an important role in conferring survival benefit. For the last three decades, great progress has been achieved in adjuvant and palliative chemotherapy. Powerful combination regimens using doublet or triplet cytotoxic agents have been developed and new molecular targeted drugs, including trastuzumab and ramucirumab, have been introduced in clinical practice. These advances have resulted from the accumulation of many clinical trials...
December 1, 2018: Japanese Journal of Clinical Oncology
Jianguo Lai, Zihao Pan, Peixian Chen, Guolin Ye, Kai Chen, Fengxi Su
Objective: Over the past decade, several studies have highlighted that axillary lymph node ratio (ratio of involved over excised axillary lymph nodes) was a superior predictor for survival outcomes compared with ypN staging. Thus, this study aimed to integrate the prognostic value of axillary lymph node ratio to improve individualized prediction of survival in node-positive breast cancer patients after neoadjuvant chemotherapy. Methods: A clinical data of 339 node-positive breast cancer patients after neoadjuvant chemotherapy from two independent centers were retrospectively reviewed...
December 1, 2018: Japanese Journal of Clinical Oncology
Sung-Soo Park, Hyeon-Seok Eom, Jin Seok Kim, Youngil Koh, Chul Won Choi, Je-Jung Lee, Kihyun Kim, Cheolwon Suh, Jae Hoon Lee, Chang-Ki Min
Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2...
November 23, 2018: Japanese Journal of Clinical Oncology
Satoru Taguchi, Hiroshi Fukuhara, Tomoki Todo
Oncolytic virus therapy is a promising new option for cancer. It utilizes genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming normal cells. T-VEC (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in 2015 and subsequently approved in Europe in 2016. Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: Pexa-Vec (pexastimogene devacirepvec), an oncolytic vaccinia virus, CG0070, an oncolytic adenovirus, and REOLYSIN (pelareorep), an oncolytic reovirus...
November 20, 2018: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"